Fatma Tuba Yildirim

Fatma Tuba Yildirim

Auto-generated profile, based on publicly available information

Fatma Tuba Yildirim

Ankara City Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
SCSelma Cakmakci
Selma Cakmakci
DODerya Ozyoruk
Derya Ozyoruk
SGServet Guresci
Servet Guresci
SOSonay Incesoy Ozdemir
Sonay Incesoy Ozdemir
FYFtama Tuba Yildirim
Ftama Tuba Yildirim
IIInci Ergurhan Ilhan
Inci Ergurhan Ilhan

19 December 2024 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
DKDilek Kaçar
Dilek Kaçar
CCCavdarli Cavdarli
Cavdarli Cavdarli
AYAyça Koca Yozgat
Ayça Koca Yozgat
MIMelek Işık
Melek Işık
FKFatma Burçin Kurtipek
Fatma Burçin Kurtipek
NYNeşe Yaralı
Neşe Yaralı
Background. The management of pediatric acute myeloid leukemia (AML) is based on the prognostic risk classification of initial leukemia. Targeted next-generation sequencing (NGS) is a reliable method used to identify recurrently mutated genes of pediatric AML and associated prognosis. Methods. In this study, we retrospectively evaluated the prognostic, and therapeutic utility of a targeted NGS panel covering twenty-five genes, in 21 children with de novo and 8 with relapsed or secondary AML. Results. Variants were detected in 44.8% of patients, and 63.2% of them were in the signaling pathway genes. The number of variants per patient and diversity increased with age. The panel results affected hematopoietic stem cell transplantation decisions, especially in core binding factor AML, and allowed the categorization of diseases according to current classifications. Panel results also pointed out predisposition to germline leukemia to the extent of the panel coverage. No targeted therapy was used based on the variants, and none of the variants were used to monitor minimal residual disease. Conclusions. Targeted NGS results, along with well-known genetic aberrations and treatment responses, can guide treatment modalities. The coverage of the routine panels should include proven mutations of childhood AML and germline leukemia predisposition genes.

1 November 2021 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
FYFatma Tuba Yildirim
Fatma Tuba Yildirim
DÖDerya Özyörük
Derya Özyörük
AEArzu Yazal Erdem
Arzu Yazal Erdem
SÇSelma Çakmakci
Selma Çakmakci
NSNeriman Sari
Neriman Sari
IIİnCi İlHan
İnCi İlHan

14 May 2026 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
AFAli Fettah
Ali Fettah
VKVolkan Köse
Volkan Köse
ASAslıhan Yüce Sezen
Aslıhan Yüce Sezen
CKCaner Kara
Caner Kara
OÇOnur Mert Çelik
Onur Mert Çelik
FYFatma Tuba Yıldırım
Fatma Tuba Yıldırım
Background. Ocular involvement in the diagnosis of leukemia is clinically important but has been reported variably. Our aim was to define its prevalence and spectrum and to identify hematologic predictors, specifically age, hemoglobin level (Hb), platelet count (PLT), mean platelet volume (MPV), and platelet mass index (PMI). Methods. This retrospective, single-center study evaluated all newly diagnosed leukemia patients between January 2023 and March 2025. All patients were examined by an ophthalmologist at the time of diagnosis and, if present, ocular involvement was identified. Results. Among 78 pediatric patients, ocular involvement was present in 17 of 78 patients (21.8%). The most common ocular manifestation was retinal hemorrhage (16.7%). Ocular involvement was more frequent in acute myeloid leukemia (AML) than in acute lymphoblastic leukemia (ALL) (46.7% vs. 15.9%, p= 0.016). Older age (for ocular involvement: median 13 years [6–15] vs. 5 years [3–11], p = 0.006; for retinal hemorrhage: median 14 years [10–15] vs. 5 years [3–11], p = 0.001) and lower hemoglobin (for ocular involvement: 6.68 ± 2.31 g/dL vs. 8.46 ± 2.47 g/dL, p = 0.01; for retinal hemorrhage: 6.33 ± 2.26 g/dL vs. 8.43 ± 2.46 g/dL, p= 0.006) were associated with a higher risk. In multivariate models, age and Hb were independent predictors of hemorrhage (age: odds ratio [OR] 1.29, 95% confidence interval [CI] 1.10–1.52 per year; Hb: OR 0.60, 95% CI 0.38–0.95 per g/dL). ROC analyses showed that age provided the best discrimination (area under the curve [AUC] 0.796; 95% CI 0.651–0.940; cut-off ≥10 years: 73% sensitivity, 70% specificity), followed by Hb (AUC 0.756; 95% CI 0.604–0.908; cut-off 6.95 g/dL: sensitivity 76%, specificity 76%), whereas PLT showed weaker discrimination (AUC 0.682; 95% CI 0.553–0.812; cut-off 48,000/mm³: sensitivity 62%, specificity 65%). Conclusion. Approximately one in five children had ocular involvement at diagnosis, most commonly retinal hemorrhage. Age and hemoglobin independently predicted retinal hemorrhage and provided useful discrimination. These data support a “hemoglobin-first” triage that prioritizes initial and follow-up ocular fundus testing in older children and those with an Hb ≲7 g/dL, with external validation of the proposed thresholds warranted.

1 November 2021 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
FYFatma Tuba Yildirim
Fatma Tuba Yildirim
DÖDerya Özyörük
Derya Özyörük
AEArzu Yazal Erdem
Arzu Yazal Erdem
SÇSelma Çakmakci
Selma Çakmakci
NSNeriman Sari
Neriman Sari
IIİnCi İlHan
İnCi İlHan